The development of lurasidone for bipolar depression

Annals of the New York Academy of Sciences
Antony LoebelAndrei A Pikalov

Abstract

Bipolar disorder is a chronic, recurrent illness that ranks among the top 10 causes of disability in the developed world. As the illness progresses, major depressive episodes increasingly predominate. However, few treatment options are available that have demonstrated efficacy in the treatment of bipolar depression, either as monotherapy or adjunctive therapy in combination with mood stabilizers. Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia. Since no previous atypical antipsychotic development program had proceeded directly from work on schizophrenia to bipolar depression, the decision to focus on this indication represented an innovation in central nervous system drug development and was designed to address a clinically significant unmet need. The current review summarizes key results of a clinical development program undertaken to characterize the efficacy and safety of lurasidone in patients diagnosed with bipolar depression. Lurasidone is currently the only treatment for bipolar depression approved in the United States as both a monotherapy and an adjunctive therapy with lithium or valproate. The approval of lurasidone expands available treatment options for pa...Continue Reading

References

Feb 1, 1992·Journal of Clinical Psychopharmacology·K T Brady, R B Lydiard
Jun 1, 1994·The Journal of Nervous and Mental Disease·S C SonneW A Morton
Nov 1, 1995·Social Psychiatry and Psychiatric Epidemiology·P Bebbington, R Ramana
Mar 24, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G B VartyM A Geyer
Sep 26, 2001·Archives of General Psychiatry·U OsbyP Sparén
Jun 5, 2002·Archives of General Psychiatry·Lewis L JuddMartin B Keller
Feb 20, 2003·The Journal of Clinical Psychiatry·Robert M A HirschfeldKaren D Wagner
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Nov 24, 2004·The Journal of Clinical Psychiatry·Joseph R CalabreseMichael L Reed
Jul 16, 2005·Biological Psychiatry·Peter B HedlundJ Gregor Sutcliffe
Aug 4, 2005·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Roger S McIntyreSidney H Kennedy
Jun 21, 2006·Journal of Psychopharmacology·Gavin P ReynoldsShona L Kirk
Jan 12, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Ross J BaldessariniJohn Hennen
May 9, 2007·Archives of General Psychiatry·Kathleen R MerikangasRonald C Kessler
Jan 22, 2008·Journal of Clinical Psychopharmacology·Michael E ThaseRandall Owen
Aug 12, 2008·Pharmacology, Biochemistry, and Behavior·Eric A StoneDavid Quartermain
Jan 27, 2009·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Liberty FajutraoAnne Heyes
Jan 30, 2009·Psychiatric Services : a Journal of the American Psychiatric Association·Babak Roshanaei-Moghaddam, Wayne Katon
Feb 13, 2009·The Journal of Clinical Psychiatry·Joseph F GoldbergMichael E Thase
Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Aug 19, 2009·The American Journal of Psychiatry·J Craig Nelson, George I Papakostas
Apr 2, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Ryan J Van Lieshout, Glenda M MacQueen
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Nov 3, 2010·The Journal of Clinical Psychiatry·Michelle M Sidor, Glenda M Macqueen
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Feb 19, 2013·Neuropharmacology·Lindsay N CatesPeter B Hedlund
Mar 20, 2013·CNS Spectrums·Michael A Cerullo, Stephen M Strakowski
Jul 19, 2013·JAMA Psychiatry·Casey CrumpJan Sundquist
May 8, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elizabeth BrunnerMichael E Thase
May 13, 2014·The Journal of Clinical Psychiatry·Terence A Ketter

❮ Previous
Next ❯

Citations

Feb 10, 2017·Psychotherapy and Psychosomatics·Ross J BaldessariniGustavo H Vázquez
Jul 9, 2020·Molecular Psychiatry·Stephen J HaggartyRoy H Perlis
Jul 26, 2018·International Journal of Molecular Sciences·Francisco López-MuñozCecilio Álamo
Jun 3, 2017·BioMed Research International·Michele FornaroAndrea de Bartolomeis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.